Labiotech.eu

News and Trends 21 Dec 2022

Poolbeg identifies new potential drug candidates for RSV infections

Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Anocca secures €25M to develop next-generation T-cell therapies for cancer

Anocca, a fully integrated cell therapy biotechnology company, has secured €25 million ($26.5 million) venture debt financing from the European Investment Bank (EIB). Anocca’s CEO and co-founder Reagan Jarvis said: “We’re delighted that the EIB has chosen to support us as we build a critical piece of advanced biotechnology capability and infrastructure in Sweden. Anocca’s […]

December 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Stem cell plasters could revolutionize heart surgeries

Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […]

December 21, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Artificial DNA can kill cancer

Researchers at the University of Tokyo in Japan have used artificial DNA to target and kill cancer cells in a new way. The method was effective in lab tests against human cervical cancer- and breast cancer-derived cells, and against malignant melanoma cells from mice. The team created a pair of chemically synthesized, hairpin-shaped, cancer-killing DNA. […]

December 21, 2022 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

December 20, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2022

Watch: Sernova’s Cell Pouch System tackles diabetes

Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System. This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Watch: Interview with IRBM’s Heidi Kingdon Jones

The IRBM Group is an innovative research and discovery CRO (contract research organization) working across all aspects of drug discovery and early development. Headquartered in Italy, the company fosters collaborations with organizations from the pharma, biotech, non-profit and academic sectors to accelerate the development of vaccines and medicines. About 250 scientists work at the company’s […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 20 Dec 2022

Watch: Valo Therapeutics at Bio-Europe

Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 20 Dec 2022

Watch: SwedenBIO leading the way

SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 300 members.

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 20 Dec 2022

Watch: Sigrid CEO talks about lifestyle diseases

Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented. The company’s research dates back to 2008 when Bengtsson and his research group at the Department of Molecular Biosciences at Stockholm University in Sweden made discoveries […]

December 20, 2022 - 1 minutemin - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Poolbeg identifies new potential drug candidates for RSV infections

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Anocca secures €25M to develop next-generation T-cell therapies for cancer

Stem cell plasters could revolutionize heart surgeries

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Artificial DNA can kill cancer

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Watch: Sernova’s Cell Pouch System tackles diabetes

Watch: Interview with IRBM’s Heidi Kingdon Jones

Watch: Valo Therapeutics at Bio-Europe

Watch: SwedenBIO leading the way

Watch: Sigrid CEO talks about lifestyle diseases

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!